Trial Profile
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study (AHELP) of Apatinib in Patients With Hepatocellular Carcinoma After Systemic TherapyChemotherapy and/or Targeted Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Carcinoma; Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms AHELP
- Sponsors Jiangsu Hengrui Medicine Co.
- 31 Jan 2021 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 04 Jul 2017 Planned number of patients changed from 360 to 400.